WARRINGTON, Pa., May 7, 2008 (PRIME NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), announced that new data supporting potential unique properties of its novel KL-4 Surfactant Replacement Technology (SRT) were presented at the Pediatric Academic Societies Annual Meeting. Preclinical studies were presented demonstrating that KL-4 does not induce an immune response known as anaphylaxis and that SURFAXIN(r) (lucinactant) displays antimicrobial properties. The Pediatric Academic Societies (PAS) Annual Meeting is internationally recognized as the largest, most relevant medical meeting dedicated to pediatric research.
